Oct 11, 2024 7:00 am EDT Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin
Oct 9, 2024 7:00 am EDT New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions
Oct 2, 2024 7:00 am EDT Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
Sep 27, 2024 5:15 pm EDT New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
Sep 23, 2024 7:00 am EDT New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
Sep 16, 2024 7:00 am EDT Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
Sep 11, 2024 7:00 am EDT DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
Sep 5, 2024 7:00 am EDT Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
